Business
Microbix Presents Molecular Pathology Platform Results
Novel Quality Controls to Enable QC & Inter-Laboratory Standardization MISSISSAUGA, ON /...
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"Microbix Presents Molecular Pathology Platform ResultsNovel Quality Controls to Enable QC & Inter-Laboratory Standardization MISSISSAUGA, ON / ACCESS Newswire / February 4, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of its novel Quality Assessment Products (\"QAPs™\") and platform technology for supporting the quality management and reproducibility of Molecular Pathology derived diagnoses of infectious diseases at Labquality Days, a lab diagnostics conference taking place in Helsinki, Finland from February 5 to 6, 2026.Molecular Pathology is the branch of medicine that integrates the use of traditional determination of cell types and tissue conformation (Pathology) with the analysis of nucleic acids (DNA or RNA) within those cells and tissues (Molecular Diagnostics). The combination of these two disciplines provides greater accuracy in disease diagnoses, as well as insights that help guide treatment decisions. In many instances, Molecular Pathology is enabled by the usage of patient tissue biopsies that have been chemically-inactivated and then set into wax, referred to as formalin-fixed paraffin-embedded (FFPE) samples.Now celebrating its 50th year, Labquality Days is an annual international scientific congress focusing on quality in laboratory medicine, developing health technologies, and clinical evidence generation. It is sponsored by Labquality Oy, a well-established Scandinavian clinical-lab external quality assessment (EQA) authority that is a Microbix customer and collaborator (https://www.labquality.com).At Labquality Days, Microbix will present a poster titled \"A Novel Platform for Simulated FFPE Quality Control Materials Enabling Inter-Laboratory Standardization.\" The poster details the results from the usage of novel Microbix QAPs for use in Molecular Pathology driven diagnosis of infections with three different infectious agents. The results establish that Microbix has developed a reproducible platform for creating FFPE-simulated quality-control (QC) materials that are homogeneous, stable, and suitable for multiple molecular pathology methods across multiple commercial instruments and tests. In the Poster, Microbix is pleased to acknowledge the support of Dartmouth-Hitchcock Medica...